Page 56 - Read Online

Page 18 of 24 Saier et al. J Cancer Metastasis Treat 2021;7:43 https://dx.doi.org/10.20517/2394-4722.2021.87

during development. Mol Cell Biol 2006;26:5015-22. DOI PubMed PMC
11. Stefan C, Jansen S, Bollen M. NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci 2005;30:542-50. DOI
PubMed
12. Nikitopoulou I, Oikonomou N, Karouzakis E, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of
modeled arthritis. J Exp Med 2012;209:925-33. DOI PubMed PMC
13. Dusaulcy R, Rancoule C, Grès S, et al. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma
lysophosphatidic acid. J Lipid Res 2011;52:1247-55. DOI PubMed PMC
14. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD. Autotaxin, an ectoenzyme that produces lysophosphatidic acid,
promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol 2008;9:415-23. DOI PubMed PMC
15. van Meeteren LA, Ruurs P, Christodoulou E, et al. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J
Biol Chem 2005;280:21155-61. DOI PubMed
16. David M, Machuca-Gayet I, Kikuta J, et al. Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast
differentiation and bone resorption activity. J Biol Chem 2014;289:6551-64. DOI PubMed PMC
17. Alioli CA, Demesmay L, Laurencin-Dalacieux S, et al. Expression of the type 1 lysophosphatidic acid receptor in osteoblastic cell
lineage controls both bone mineralization and osteocyte specification. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158715.
DOI PubMed
18. Pasternack SM, von Kügelgen I, Al Aboud K, et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance
of human hair growth. Nat Genet 2008;40:329-34. DOI PubMed
19. Boucharaba A, Serre CM, Grès S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases
in breast cancer. J Clin Invest 2004;114:1714-25. DOI PubMed PMC
20. Blackburn J, Mansell JP. The emerging role of lysophosphatidic acid (LPA) in skeletal biology. Bone 2012;50:756-62. DOI PubMed
21. Gennero I, Laurencin-Dalicieux S, Conte-Auriol F, et al. Absence of the lysophosphatidic acid receptor LPA1 results in abnormal
bone development and decreased bone mass. Bone 2011;49:395-403. DOI PubMed PMC
22. Liu YB, Kharode Y, Bodine PV, Yaworsky PJ, Robinson JA, Billiard J. LPA induces osteoblast differentiation through interplay of
two receptors: LPA1 and LPA4. J Cell Biochem 2010;109:794-800. DOI PubMed
23. Lapierre DM, Tanabe N, Pereverzev A, et al. Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate
cytosolic calcium concentration, evoke retraction, and promote cell survival. J Biol Chem 2010;285:25792-801. DOI PubMed PMC
24. Karagiosis SA, Karin NJ. Lysophosphatidic acid induces osteocyte dendrite outgrowth. Biochem Biophys Res Commun
2007;357:194-9. DOI PubMed
25. McMichael BK, Meyer SM, Lee BS. c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6)
promotes osteoclast sealing zone formation. J Biol Chem 2010;285:26641-51. DOI PubMed PMC
26. David M, Wannecq E, Descotes F, et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through
lysophosphatidic acid-dependent activation of osteoclasts. PLoS One 2010;5:e9741. DOI PubMed PMC
27. Miyabe Y, Miyabe C, Iwai Y, et al. Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis Rheum
2013;65:2037-47. DOI PubMed
28. Flammier S, Peyruchaud O, Bourguillault F, et al. Osteoclast-derived autotaxin, a distinguishing factor for inflammatory bone loss.
Arthritis Rheumatol 2019;71:1801-11. DOI PubMed PMC
29. Leblanc R, Lee SC, David M, et al. Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast
cancer cells to bone. Blood 2014;124:3141-50. DOI PubMed PMC
30. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, et al. Identification, purification, and partial sequence
analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992;267:2524-9. PubMed
31. Lin ME, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other
Lipid Mediat 2010;91:130-8. DOI PubMed PMC
32. Choi JW, Herr DR, Noguchi K, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010;50:157-86.
DOI PubMed
33. Sedláková I, Vávrová J, Tošner J, Hanousek L. Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer. Tumour Biol
2011;32:311-6. DOI PubMed
34. Ikeda H, Enooku K, Ohkawa R, Koike K, Yatomi Y. Plasma lysophosphatidic acid levels and hepatocellular carcinoma. Hepatology
2013;57:417-8. DOI PubMed
35. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995;309:933-40. DOI
PubMed PMC
36. Lin CI, Chen CN, Huang MT, et al. Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in
human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation- and EGFR transactivation-dependent mechanisms.
Cell Signal 2008;20:1804-14. DOI PubMed
37. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012;72:1909-14. DOI
PubMed PMC
38. Bellahcène A, Bachelier R, Detry C, Lidereau R, Clézardin P, Castronovo V. Transcriptome analysis reveals an osteoblast-like
phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 2007;101:135-48. DOI PubMed
39. Wu X, Ma Y, Chen H, et al. Lysophosphatidic acid induces interleukin-6 and CXCL15 secretion from MLO-Y4 cells through
activation of the LPA receptor and PKCθ signaling pathway. Int Immunopharmacol 2019;74:105664. DOI PubMed
1
40. Aki Y, Kondo A, Nakamura H, Togari A. Lysophosphatidic acid-stimulated interleukin-6 and -8 synthesis through LPA1 receptors